Humira passes post-marketing muster in Japan psoriasis setting
This article was originally published in Scrip
Abbott/Eisai's Humira (adalimumab) has cleared its conditional approval period in Japan for the additional indication of plaque psoriasis and psoriasis arthropica, clearing the way for the wider use of the product in this setting.
You may also be interested in...
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Japanese major builds presence in novel device technology beyond its conventional therapeutics as looks towards a more holistic future of care.